𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genomic DNA and messenger rna expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines

✍ Scribed by Xiaoling Zhou; Hiroyuki Suzuki; Yutaka Shimada; Masayuki Imamura; Jing Yin; Hai-Yan Jiang; Lila Tarmin; John M. Abraham; Stephen J. Meltzer


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
496 KB
Volume
13
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The genes CDKN2B (MTS2) and CDKN2 (MTSI) encoding the proteins p15 and p16 are both located on chromosomal band 9p21, a locus at which frequent homozygous and heterozygous deletions occur in many primary human tumors, including esophageal carcinoma. CDKN2 and CDKN2B belong to a family of cyclin‐dependent kinase 4 inhibitors (INK41) and control cell proliferation during the GI phase of the cell cycle. Their inactivation may contribute to uncontrolled growth in human cancers. To investigate whether CDKN2B and CDKN2 are involved in esophageal tumorigenesis, we studied homozygous deletion, intragenic mutation, and messenger RNA (mRNA) expression of CDKN2 and CDKN2B in nine esophageal squamous cancer cell lines. Polymerase chain reaction (PCR) amplification revealed that five of the nine cell lines (55%) manifested homozygous deletions of CDKN2B, CDKN2, and/or flanking loci on chromosomal band 9p21. Reverse transcriptase‐PCR (RT‐PCR) was used to examine CDKN2 and CDKN2B mRNA in the nine cell lines. Lack of CDKN2 and CDKN2B mRNA correlated perfectly with homozygous deletion involving these genes. No subtle intragenic mutations of CDKN2B or __CDKN2__were detected by DNA sequencing of their entire coding sequences in any cell lines lacking homozygous deletion. Two of the cell lines manifested homozygous deletions excluding CDKN2; one of these two deletions also excluded CDKN2B. These results suggest that inactivation of CDKN2B and CDKN2 may contribute to the malignant phenotype in esophageal cells and that homozygous deletion may be the predominant mechanism for inactivation of CDKN2B and CDKN2. Alternatively, a gene or genes adjacent to CDKN2B/CDKN2 may constitute the target(s) of deletion at this locus. © 1995 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Homozygous Deletions and Loss of Express
✍ William M. Lydiatt; V. V. V. S. Murty; Bruce J. Davidson; Li Xu; Katerina Dyomin 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB

Deletion of 9~21-22 is a common genetic alteration in dysplastic. in situ, and invasive head and neck squamous cell carcinoma (HNSCC). However, a candidate tumor suppressor gene (TSG) at this site has thus far not been identified in HNSCC. We report homozygous deletion of the recently identified mul

DNA studies underestimate the major role
✍ Chu Lee Wu; Luca Roz; Susan McKown; Philip Sloan; Andrew P. Read; Susan Holland; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

Loss of CDKN2A expression was demonstrated by immunohistochemistry in 87% of oral and oropharyngeal squamous cell carcinoma (OSCC) primary tumor samples. By contrast, DNA studies showed a much lower frequency of loss of the CDKN2A gene. Point mutations and promoter methylation of CDKN2A were seen in